Alterity Therapeutics is an ASX-listed company that’s focused on developing treatments for devastating conditions like Parkinson’s disease and Multiple System Atrophy. 

And it’s a long way down the path with one of its treatments, having just completed its phase two clinical trial.

Dr David Stamler, Chief Executive of Alterity Therapeutics, talks to Sean Aylmer about the path to developing new treatments, and what a successful treatment would mean for patients.

Alterity Therapeutics is a supporter of Fear & Greed